Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Wolfspeed Shares Plunge on Bleak Financial Forecast

Robert Sasse by Robert Sasse
November 2, 2025
in Earnings, Nasdaq, Semiconductors
0
Wolfspeed Stock
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

Wolfspeed investors faced a severe market setback as the company’s disappointing outlook triggered a dramatic selloff. The semiconductor firm’s latest quarterly results were completely overshadowed by a guidance that fell substantially below market expectations.

Market Reaction and Trading Impact

The financial markets delivered a harsh verdict on Wolfspeed’s projections. During Thursday’s session on October 31, the stock experienced a massive gap down at market open. Shares plummeted from their previous close of $31.99 to open at just $25.94, representing a nearly 19% single-day collapse. This violent price movement underscores investor anxiety about the company’s immediate challenges, particularly given its recent emergence from bankruptcy protection.

Concerning Guidance Details

The primary driver behind the market’s negative response emerged from Wolfspeed’s second-quarter revenue forecast. Management projected sales between $150 million and $190 million, significantly missing the $202.7 million consensus estimate among market analysts. The midpoint of the company’s guidance falls approximately 16% below expectations.

More troubling for long-term investors, company leadership indicated they anticipate market weakness to persist through the 2026 fiscal year.

Should investors sell immediately? Or is it worth buying Wolfspeed?

Quarterly Performance Breakdown

While Wolfspeed’s first-quarter results presented a mixed picture, the disappointing forward guidance dominated investor attention:

  • Q2 Revenue Guidance: $150-190 million (versus $202.7 million consensus)
  • Q1 Actual Revenue: $196.8 million (representing 1.1% year-over-year growth but falling short of the $198 million expectation)
  • Q1 Adjusted EPS: Loss of $0.55 per share (improved from the projected loss between $0.67 and $0.71)
  • Q1 Adjusted Gross Margin: Sharp decline to -26% (compared to positive 3% in the prior-year period)

The gross margin contraction from positive territory to negative 26% stands out as particularly alarming to financial observers.

Analyst Community Response

Financial research firms issued strongly worded assessments following the guidance announcement. Weiss Ratings maintained its “Sell” recommendation, while Wall Street Zen downgraded the stock from “Hold” to “Sell.” Susquehanna provided the lone moderately positive note with a “Neutral” rating and $30 price target.

The overall analyst sentiment remains pessimistic, with the current consensus showing five “Sell” recommendations outweighing four “Buy” ratings and a single “Hold” opinion.

Ad

Wolfspeed Stock: Buy or Sell?! New Wolfspeed Analysis from March 25 delivers the answer:

The latest Wolfspeed figures speak for themselves: Urgent action needed for Wolfspeed investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Wolfspeed: Buy or sell? Read more here...

Tags: Wolfspeed
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
MongoDB Stock
AI & Quantum Computing

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock
Analysis

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026
Next Post
Coinbase Stock

Coinbase Shares Surge as Crypto Rally Fuels Record Earnings

Eli Lilly Stock

Eli Lilly Shatters Expectations with Record Quarterly Performance

Tesla Stock

Tesla's Q3 Performance Reveals Deepening Profitability Crisis

Recommended

iRadimed Stock

iRadimed: Record Performance Meets Divergent Institutional Strategies

7 months ago
Alphabet Stock

Alphabet Shares Under Scrutiny as CEO Pichai Executes Multi-Million Dollar Stock Sale

6 months ago
Bloom Energy Stock

Bloom Energy Shares Plunge Following Spectacular Rally

4 months ago
Strategy Stock

Strategy Shares Plunge Following Dual Capital Raise Announcement

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Hesai Group’s Milestone Profit Tempered by Cautious Guidance

Trending

Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

by SiterGedge
March 25, 2026
0

As Humacyte prepares to release its full-year 2025 financial results, the biotechnology firm finds its stock trading...

Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026
Hain Celestial Stock

Hain Celestial Sheds Snack Division in Strategic Overhaul

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline
  • MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com